RISK-BASED SCREENING FOR CERVICAL CANCER

Akronyymi

RISCC

Rahoitetun hankkeen kuvaus

Screening for cervical cancer is a globally recommended public health policy. Many risk factors are known, but so far only “one-size-fits-all” screening programs have been implemented, providing suboptimal protection for women at high risk, suboptimal allocation of resources and substantial screening-related harms. Development of risk-stratified screening is a priority, because cervical cancer is on the rise in many countries, the uptake of screening remains moderate in subpopulations at high risk, and costs related to screening are high. RISCC will develop risk-based screening based on screening history, HPV vaccination status and other relevant risk factors. Risk profiles based on screening history will be developed using joint data from several large European randomized HPV screening trials with long-term follow-up, HPV self-sampling trials, and registries of both cytology- and HPV-based screening programs. Risk profiles based on vaccination status will be developed for cohorts with varying screening and vaccination coverage using data from a community randomized vaccination trial, linked vaccination/screening/cancer registries, and a cohort of women vaccinated at screening age. Risk-based screening algorithms will be evaluated with respect to effectiveness, harms and costs by predictive and health-economic modelling. Finally, open source e-health and m-health applications using the risk-based screening algorithms will be developed to support implementation into real-life programs. The use of risk-based screening and a digital platform for screening invitations will be evaluated in an implementation trial within the Swedish organized screening program. The RISCC risk-based approach to cervical screening is directly related to the work program as it is based on a wealth of data sources on different, important risk factors for cervical cancer, builds on open science enabling citizens, and could thus constitute a role model for personalized screening.
Näytä enemmän

Aloitusvuosi

2020

Päättymisvuosi

2024

Myönnetty rahoitus

PIRKANMAAN HYVINVOINTIALUE
1 191 708.75 €
Participant
SCIENSANO (BE)
662 958.34 €
Participant
EUROPEAN SOCIETY OF GYNAECOLOGICAL (CH)
112 500 €
Participant
STICHTING VUMC (NL)
1 584 871.66 €
Coordinator
AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO (IT)
256 250 €
Participant
SELF-SCREEN BV (NL)
300 000 €
Participant
INSTITUT CATALA D'ONCOLOGIA (ES)
378 125 €
Participant
CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER (FR)
Participant
STOCKHOLMS LANS LANDSTING (SE)
200 000 €
Participant
UNIVERZA V LJUBLJANI (SI)
250 461.25 €
Participant
KAROLINSKA INSTITUTET (SE)
855 480 €
Participant

Myönnetty summa

5 792 355 €

Rahoittaja

Euroopan unioni

Rahoitusmuoto

Research and Innovation action

Puiteohjelma

Horizon 2020 Framework Programme

Haku

Ohjelman osa
Health (5290)
Preventing disease (5295)
Aihe
Towards risk-based screening strategies for non-communicable diseases (SC1-BHC-30-2019)
Haun tunniste
H2020-SC1-2019-Two-Stage-RTD

Muut tiedot

Rahoituspäätöksen numero

847845

Tunnistetut aiheet

cancer